单唾液酸四己糖神经节苷脂钠联合鼠神经生长因子治疗Bell面瘫的回顾性研究

发布时间：2018-05-15 20:28

本文选题：单唾液酸四己糖神经节苷脂钠 + 鼠神经生长因子　；参考：《南京医科大学学报(自然科学版)》2017年11期

【摘要】：目的:探讨单唾液酸四己糖神经节苷脂钠(monosialotetrahexosylganglioside,GM1)联合鼠神经生长因子(nerve growth factor,NGF)在早期治疗Bell面瘫的临床疗效和短期预后。方法 :回顾比较分析2009年1月—2015年9月219例Bell面瘫病例,其中GM1联合NGF组58例,GM1组55例,NGF组51例,未用特殊营养神经药物的基础组55例。所有病例基础治疗相同。通过比较治疗前及治疗后1、2、4周House-Brackmann分级、Sunny Brook综合评分,评价面神经功能的恢复程度。结果:GM1联合NGF组在治疗后2、4周的House-Brackmann分级及Sunny Brook评分均明显优于其他组,差异有统计学意义(P0.01)。GM1联合NGF组在治疗后4周的痊愈率(91.4%)明显高于GM1组(74.5%)、NGF组(78.4%)及基础组(50.9%),差异有统计学意义(P0.01)。结论:GM1联合NGF早期治疗Bell面瘫,在面神经功能的早期恢复和改善短期预后方面具有优势。
[Abstract]:Objective: to investigate the clinical efficacy and short-term prognosis of monosialotetrahexosylganglioside (GM1) combined with nerve growth factor (NGF) in the early treatment of Bell facial paralysis. Methods: 219 cases of Bell facial paralysis from January 2009 to September 2015 were retrospectively analyzed, including 58 cases of GM1 combined with NGF group (55 cases of GM1 group) and 55 cases of basic group without special neurotrophic drugs. Basic treatment was the same in all cases. The recovery degree of facial nerve function was evaluated by comparing the comprehensive score of Sunny Brook with House-Brackmann classification before treatment and 1: 2 weeks after treatment. Results the House-Brackmann grading and Sunny Brook score in the NGF group were significantly better than those in the other groups at 2 weeks after treatment. The recovery rate was 91.4 in the P0.01 + GM1 + NGF group at 4 weeks after treatment. It was significantly higher in the GM1 group than in the GM1 group (74.5%) and in the basic group (50.9%). The difference was statistically significant (P 0.01). Conclusion early treatment of Bell facial paralysis with NGF combined with GM1 has advantages in early recovery of facial nerve function and improvement of short-term prognosis.
【作者单位】：南京医科大学第二附属医院神经内科;
【基金】：国家自然科学基金(81301313) 江苏省自然科学基金(BK20131015) 南京市医学科技发展专项资金(YKK13174)
【分类号】：R745.12

【相似文献】